Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
22/07/2026 24:53
BRIEF-Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective Hanall Biopharma Co Ltd 009420.KS:
ICC RULES LICENSING DEAL WITH HARBOUR BIOMED CONTINUES TO BE EFFECTIVE
Source text: [ID:]
Further company coverage: 009420.KS
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies